SOURCE: IR Biosciences, Inc.

April 30, 2007 07:00 ET

ImmuneRegen BioSciences Appoints Dr. Frederick "Skip" M. Burkle, Jr. to Advisory Board

Noted Expert in Infectious Disease and Disaster Management to Help Company Develop Viprovex and Radilex

SCOTTSDALE, AZ -- (MARKET WIRE) -- April 30, 2007 -- ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), announced today the appointment of Frederick "Skip" M. Burkle, Jr. to its Bioterrorism/Pandemic Influenza Advisory Board. Dr. Burkle is internationally recognized as an expert in infectious diseases in developing countries, management of humanitarian emergencies and disaster medicine, and for his work as a physician, professor and author. Dr. Burkle's expertise will be valuable in the planning and implementation of educational activities surrounding ImmuneRegen's Homspera and in guiding the development of Viprovex and Radilex for the potential use in international crises, including those related to biodefense/Pandemic Flu related causes.

Dr. Burkle is currently Director, Asia-Pacific Center for Biosecurity, Disaster & Conflict Research, and a Professor in Tropical Medicine, Public Health and Epidemiology, at the University of Hawaii's John A. Burns School of Medicine. He also serves as Senior Fellow, the Harvard Humanitarian Initiative and Director of the Asia-Pacific Branch and Senior Scholar, Scientist, and Visiting Professor at John Hopkins University Medical Institutes' Center for Refugee & Disaster Response.

From 2002-03 he served as Deputy Assistant Administrator for the Bureau of Global Health at the U.S. Agency for International Development, U.S. Department of State and was appointed the Minister of Health to Iraq. From 1989 to 2000, he was Professor of Pediatrics, Surgery and Public Health and Chairman, and Chair of the Division of Emergency Medicine, Department of Surgery, University of Hawaii Schools of Medicine and Public Health. He is Adjunct Professor, The African Center for Strategic Studies, the Uniformed Services University of Health Sciences, and the Tulane University School of Public Health in New Orleans. He served as the Senior Advisor in Medicine and Public Health for the Defense Threat Reduction Agency (DTRA) and as a Research Scientist for the Centers for Disease Control and Prevention (CDC).

"We are honored to have attracted such an accomplished expert in the area of infectious disease management as Dr. Burkle to our Company," said IR BioSciences' CEO Michael K. Wilhelm. "We work well with Dr. Burkle and together we believe Viprovex and Radilex represent promising solutions to biodefense/Pandemic Flu situations and look forward to Dr. Burkle's counsel in helping us in our national and international educational efforts regarding our drug candidate and its development."

Dr. Burkle explained his interest in working with ImmuneRegen from the public health perspective. "I'm interested in working with ImmuneRegen because our present defenses against pandemic influenza are limited to social distancing, anti-virals and vaccines. We need many more tools and techniques to help control future outbreaks. ImmuneRegen's current work with a broad ranging adjuvant is exciting, as adjuvant care is one of those tools that require enhanced studies and research to bring the promise of a chance for survival to the world's population, especially those most vulnerable to co-morbid diseases and suffering from malnutrition, as we so often see in developing countries," said Dr. Burkle.

Dr. Burkle is a graduate of Saint Michael's College (1961) and the University of Vermont College of Medicine (1965). He holds post-graduate degrees from Yale, Harvard, Dartmouth, the University of California at Berkeley, a Diploma from the University of Geneva, Switzerland, in Health Emergencies in Large Populations, and a diploma in tropical medicine from the Royal College of Surgeons in Ireland. He is qualified in Emergency Medicine, Pediatrics, Pediatric Emergency Medicine, and Psychiatry and holds a Master's Degree in Public Health. He is a Fellow of the American College of Emergency Physicians and the American Academy of Pediatrics, and received the Emergency Physician of the Year Award in 1999 from the Governor of Hawaii.

Professor Burkle has published over 110 scientific articles, abstracts and book chapters, and four books, three on disaster management, including "Disaster Medicine," a seminal text on the emergency response to disasters (1984). He has worked in and consulted on humanitarian emergencies and large-scale international disasters in Asia, Africa, Middle East and Eastern Europe and serves as an International Health Delegate to the Red Cross.

Dr. Burkle has received numerous "Excellence in Teaching" and humanitarian service awards. These include the prestigious Gorgas Medal for "distinguished work in preventive medicine, groundbreaking work in disaster management and humanitarian assistance and the training of an entire generation of U.S. and international personnel," the Cook Award for Humanitarian Service, and the Humanitarian Award from the International Federation of Emergency Medicine. In 2005 he received the University of Vermont College of Medicine Alumni Association Award for Community Service in Medicine for his "distinguished career in humanitarian and military service." He is a member of the Board of Directors of the International Rescue Committee, the world's largest refugee NGO, headquartered in New York City and was their Executive Medical Director in 1999. He currently serves as the Disaster Chairman, Hawaii Chapter, American Red Cross.

About ImmuneRegen BioSciences, Inc.

IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera™ and its derivatives Radilex™ and Viprovex™, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at

Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the subsequent investigations were limited in scope, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in the Company's Form 10-KSB for the twelve months ended December 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.

Contact Information